At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 28 enrolled
Drug / intervention
rDEN2/4delta30(ME) Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Study of the Safety and Immunogenicity of rDEN2/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 2
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Oct 22, 2004·Updated Jan 21, 2008
In Brief
A Phase 1 clinical trial evaluating rDEN2/4delta30(ME) Vaccine and Placebo for Dengue Fever. Completed, enrolled 28 participants across 1 site.
Detailed Summary
Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in healthy adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue Fever
CountriesUnited States
CollaboratorsJohns Hopkins Bloomberg School of Public Health
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2004
Enrollment StartJan 2005
Primary CompletionApr 2006
TodayJul 2026
First PostedOct 22, 2004
Enrollment StartJan 1, 2005
Primary CompletionApr 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 21.7 years ago
Interventions
rDEN2/4delta30(ME) Vaccinebiological
Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
Placebobiological
Placebo for rDEN2/4delta30(ME) vaccine